Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has shared an update.
Thiogenesis Therapeutics Corp has initiated a Phase 2 clinical trial for its lead product candidate, TTI-0102, aimed at treating the mitochondrial disease MELAS. The trial, conducted in the Netherlands and France, will assess the safety and efficacy of TTI-0102, a prodrug designed to increase antioxidant levels in patients, potentially addressing a significant unmet need in the treatment of MELAS, a prevalent yet orphan mitochondrial disorder.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company based in San Diego, California. It focuses on developing disulfides that enhance the production of intracellular antioxidants and therapeutic compounds, with a market focus on treating inherited mitochondrial diseases.
Average Trading Volume: 29,325
Technical Sentiment Signal: Sell
Current Market Cap: C$30.1M
See more insights into TTI stock on TipRanks’ Stock Analysis page.